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Abstract
In Parkinson’s disease and other Lewy body disorders, the propagation of pathology has been accredited to the spreading 
of extracellular α-synuclein (α-syn). Although the pathogenic mechanisms are not fully understood, cell-to-cell transfer 
of α-syn via exosomes and other extracellular vesicles (EVs) has been reported. Here, we investigated whether altered 
molecular properties of α-syn can influence the distribution and secretion of α-syn in human neuroblastoma cells. Differ-
ent α-syn variants, including α-syn:hemi-Venus and disease-causing mutants, were overexpressed and EVs were isolated 
from the conditioned medium. Of the secreted α-syn, 0.1–2% was associated with vesicles. The major part of EV α-syn was 
attached to the outer membrane of vesicles, whereas a smaller fraction was found in their lumen. For α-syn expressed with 
N-terminal hemi-Venus, the relative levels associated with EVs were higher than for WT α-syn. Moreover, such EV-associated 
α-syn:hemi-Venus species were internalized in recipient cells to a higher degree than the corresponding free-floating forms. 
Among the disease-causing mutants, A53T α-syn displayed an increased association with EVs. Taken together, our data sug-
gest that α-syn species with presumably lost physiological functions or altered aggregation properties may shift the cellular 
processing towards vesicular secretion. Our findings thus lend further support to the tenet that EVs can mediate spreading 
of harmful α-syn species and thereby contribute to the pathology in α-synucleinopathies.
Keywords Alpha-synuclein · Parkinson’s disease · Alpha-synuclein oligomers · Human neuroblastoma · Extracellular 
vesicles · Exosomes
Background
Parkinson’s disease (PD) and dementia with Lewy bod-
ies (DLB) are the two most common disorders with Lewy 
body and Lewy neurite pathology. Such intracellular inclu-
sions mainly consist of misfolded, aggregated forms of 
α-synuclein (α-syn) (Spillantini et  al. 1997) and recent 
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research has indicated that various soluble α-syn oligomers 
are the most toxic species, leading to neuroinflammation 
(Lee et al. 2010), oxidative stress (Unal-Cevik et al. 2011), 
and neurotoxicity (Diogenes et al. 2012; Winner et al. 2011).
The presence of α-syn inclusions in fetal tissue grafts 
10–15 years after transplantation in PD patients suggests 
that cell-to-cell propagation occurs in the affected brain 
(Kordower et al. 2008; Li et al. 2008). In addition, accu-
mulating evidence from cell-based studies suggests that 
α-syn can spread readily between cells (Domert et al. 2016; 
Hansen et al. 2011). It has also been demonstrated that 
transfer can occur not only between neurons, but also from 
neurons to glial cells (Reyes et al. 2014) as well as between 
glial cells (Rostami et al. 2017). Oligomers of α-syn seem 
to be particularly prone to spread (Danzer et al. 2012) and 
may also have a capacity to sequester monomeric protein in 
recipient cells, suggesting that they can be responsible for 
a prion-like propagation of pathology (Danzer et al. 2009). 
Via such mechanisms, α-syn could spread from one brain 
region to another, which would explain the hierarchical pat-
tern by which pathology occurs in the PD brain (Braak et al. 
2006b). Moreover, the discovery of early α-syn pathology 
in the nerve plexus of the gastrointestinal tract suggests that 
pathology may even initiate outside the central nervous sys-
tem (CNS) and transfer to the brain stem via enteric neurons 
(Braak et al. 2006a).
It is not known by which mechanisms α-syn can spread 
between cells, but it has been suggested that one route may 
be via active secretion to the extracellular space, followed by 
ingestion of recipient cells (Reyes et al. 2015). Such inter-
cellular transport could take place via conventional exocy-
tosis or via exosomes and other extracellular vesicles (EVs) 
(Faure et al. 2006). Exosomes are intraluminal vesicles of 
endocytic origin (Valadi et al. 2007), secreted via multive-
sicular bodies (Subra et al. 2010), whereas other EVs are 
budding directly from the cell membrane. Exosomes are 
believed to work as vectors of cell-to-cell transmission of 
RNA (Valadi et al. 2007), proteins and lipids (Subra et al. 
2010).
Previous studies suggest that α-syn is present in exosomes 
from cultured cells and that the formation of oligomers 
(Danzer et al. 2012) and other aggregates (Grey et al. 2015; 
Lee et al. 2005) can be enhanced in this environment. When 
inhibiting lysosomal action in α-syn overexpressing neural 
cell lines, exosomal secretion of α-syn increased and pro-
moted cell-to-cell transfer of α-syn (Alvarez-Erviti et al. 
2011). Moreover, cell-derived exosomes containing α-syn 
were found to induce cell death in neuronal cells (Emman-
ouilidou et al. 2010).
Alpha-synuclein can be detected both within and on the 
outside of exosomes and other extracellular vesicles (Danzer 
et al. 2012), suggesting that EV secretion is a plausible 
mechanism for spreading of toxic α-syn species between 
cells in the CNS. However, the underlying mechanisms regu-
lating the sorting and releasing of α-syn into EVs are still 
poorly understood.
Different forms of α-syn may be sorted for EV release at 
different rates. For example, the various forms of fluores-
cently labeled α-syn that are often used in ex vivo experi-
mental models for α-syn oligomerization may be differently 
processed by the cells compared to the physiological protein 
forms. It is also possible that the different α-syn mutants 
that cause familial forms of Lewy body disorders (reviewed 
in Lill 2016) may differ from the non-mutated form in this 
respect. Moreover, it is not clear if this regulation is depend-
ent on the presence of other proteins, such as the PD-related 
molecules leucine-rich repeat kinase 2 (LRRK2) (Xiong 
et al. 2010), vacuolar protein sorting-associated protein 35 
(VPS35) (Zavodszky et al. 2014), and ATP13A2 (Tsunemi 
et al. 2014).
In this study, we wanted to assess how different forms of 
α-syn are processed by cells for EV or non-vesicular secre-
tion. For this purpose, we investigated cultured human neu-
roblastoma cells overexpressing regular wild-type α-syn as 
well as α-syn incorporated in a fluorescent oligomerization 
assay or containing any of the six disease-causing mutations 
(Lazaro et al. 2016, 2014). We also wanted to analyze if 
vesicular-associated α-syn could be internalized in recipient 
cells to a greater extent than secreted free-floating α-syn.
Materials and Methods
Cell Culture and Transient α‑Synuclein 
Overexpression
The human neuroblastoma cell line SH-SY5Y (94,030,304, 
Sigma-Aldrich, Saint Louis, MO) was used for transient 
α-syn expression. Cells were cultured in Opti-MEM-reduced 
serum medium supplemented with 5% FBS (SV30160.03, 
HyClone, GE Healthcare, Chicago, IL) and Penicillin/Strep-
tomycin (15,140,122, Life Technologies, Carlsbad, CA). For 
transfections, cells were seeded in 60 mm Petri dishes and 
transiently transfected with plasmids encoding the differ-
ent α-syn constructs. Lipofectamine 2000 (11,668,030, Life 
Technologies) was used for the transfections. The plasmids 
used were pcDNA3.1+ with the following inserts: wild-type 
α-syn (WT), hemi-peptides of Venus yellow fluorescent 
protein (YFP) fused to full-length wild-type α-syn (Venus 
1–157 N-terminally fused to α-syn (V1S), Venus 158–238 
C-terminally fused to α-syn (SV2) or V1S + SV2 at an equal 
ratio (BiFC)) (Fig. 1a), α-syn-2A full-length green fluores-
cent protein (GFP), or α-syn with any of the six disease-
causing point mutations (A30P, E46K, H50Q, G51D, A53E, 
and A53T). The total amount of DNA was kept constant for 
both single and double transfections. After overnight (O/N) 
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transfection, cells were washed and kept in medium with 
5% FBS for 24 h. The FBS had been vesicle-depleted by 
ultracentrifugation at 4 °C at 120,000×g for 17 h, in a fixed 
angle rotor (Ti70, Beckman Coulter, Brea, CA).
Tau Expression
Tau proteins were expressed with or without a GFP tag. This 
protein makes a relevant control since it is expressed intra-
cellularly and forms both oligomers as well as larger aggre-
gates (as neurofibrillary tangles) (Lasagna-Reeves et al. 
2012). Plasmids encoding tau or tau fused to full-length GFP 
were transfected as described above.
Sample Preparation
To remove dead cells and debris, the conditioned medium 
was filtered through a 0.45 µm syringe filter (2,542,903, 
PerkinElmer, Waltham, MA) and stored at − 20 °C. For 
intracellular (IC) protein analysis, cells were lysed for 
30 min on ice in 1x RIPA buffer (ab156034, Abcam, Cam-
bridge, UK) with a protease inhibitor cocktail (78,430 
Thermo Fisher Scientific, Waltham, MA) and stored at 
− 70 °C. Prior to analysis, the lysate was thawed on ice and 
centrifuged at 12,000×g, 4 °C for 30 min. The supernatant 
was transferred to a new tube and stored at − 20 °C as the IC 
fraction. The conditioned medium was thawed and centri-
fuged at 100,000×g at 4 °C for 2 h in a fixed angle rotor. The 
supernatant was collected as the extracellular free-floating 
protein (FFP) fraction. The pellet was washed once in 500 µl 
PBS, which had been filtrated twice in a 0.22 µm Millex 
syringe filter unit (Millipore, Burlington, MA), transferred to 
a new centrifuge tube, and recentrifuged as above. The ensu-
ing pellet, containing enriched EVs, was resuspended in PBS 
(0.1% BSA) and split in two equal volumes. These were then 
diluted in either PBS (0.1% BSA) or in RIPA buffer with 
the protease inhibitor cocktail (Thermo Fisher Scientific) 
to generate the two respective EV fractions (RIPA− and 
RIPA+) (Fig. 1b).
For the uptake experiments, the same protocol as above 
was used, except that no detergent was applied.
Western Blot
After ultracentrifugation, the pellets were lysed directly in 
a total volume of 150 µl RIPA buffer with a protease inhibi-
tor cocktail (Thermo Fisher Scientific). The same volumes 
of the original samples were added to each well. A total 
Fig. 1  Preparation of cell-derived samples for the study of α-syn 
secretion. a In addition to human WT α-syn, the V1S (yellow) 
and SV2 (blue) constructs (α-syn fused with either half of Venus) 
were used. Also, V1S and SV2 were co-transfected in a BiFC. The 
N-terminal region of the α-syn portion is shown in red, whereas the 
C-terminal region is shown in gray. Upon α-syn dimerization of V1S 
and SV2, the protein aggregate fluoresces (green). b SH-SY5Y cells 
were transfected overnight. The cells were washed once in medium, 
followed by incubation for 24 h. The ensuing medium was collected, 
filtered to remove dead cells and debris, ultracentrifuged, upon which 
the transfected cells were washed in PBS and lysed in RIPA for the IC 
fraction. The medium supernatant, from the ultracentrifugation (FFP) 
was saved, after which the pellet was washed once followed by an 
exchange of tubes before the second ultracentrifugation. The ensuing 
pellet was reconstituted in PBS, split in two before adding either 2 × 
RIPA at a 1:1 ratio (EV RIPA+) or additional PBS at a 1:1 ratio (EV 
RIPA−), to get the two EV fractions
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sample volume of 60 µl of EV and FFP fractions was run 
under reducing conditions on a 4–12% Bis-Tris gel for 
approximately 80 min at 150 V. Gels were transferred to 
a nitrocellulose membrane. Ponceau S was used to ensure 
proper transfer. Blocking was carried out at room tempera-
ture (RT) for 1 h with 5% dry milk in TBS-T before incuba-
tion with primary antibodies and after stripping with 0.4M 
NaOH at RT for 5 min. The membranes were incubated with 
primary antibodies against L1CAM (ab3200, Abcam), Alix 
(sc-53538, Santa Cruz Biotechnology, Dallas, TX), Flotil-
lin-1 (610820, BD Biosciences), and CD63 (sc-15363, Santa 
Cruz Biotechnology). All antibodies were incubated in 5% 
milk in TBS-T (1:1000) O/N at 4 °C. HRP-linked secondary 
antibodies against rabbit (GE Healthcare) or mouse (Bio-
Rad, Hercules, CA) IgG were used at a 1:20,000 dilution in 
5% milk at RT for 1 h and ECL Prime (GE Healthcare) was 
used for development on Amersham Hyperfilm ECL (GE 
Healthcare).
NanoSight Analyses
The average size and the standard deviation of the EVs in 
the EV and FFP fractions was determined using NanoSight 
(Malvern Instruments, Malvern, UK) from one example 
series of transfected cells.
Transmission Electron Microscopy (TEM)
Conditioned medium was collected from SH-SY5Y cells 
after 24 h of incubation and fixed in 2.5% glutaraldehyde at 
4 °C for 3 d. The solution was filtrated through a 0.45 µm 
syringe filter (Millipore) and centrifuged at 100,000×g at 
4 °C for 2 h. The supernatant was analyzed as the FFP frac-
tion. The pellet was resuspended in glutaraldehyde and cen-
trifuged as above. The final pellet was resuspended in glutar-
aldehyde and analyzed as the EV fraction. All samples were 
kept at 4 °C until TEM analysis. Solutions were diluted 1:2 
and stained with uranyl acetate. The samples were imaged 
with an H-7100 transmission electron microscope (Hitachi, 
Chiyoda, Japan).
Alpha‑Synuclein ELISA
High-binding half area plates (Costar, Sigma-Aldrich) were 
coated overnight with Syn-1 (Clone 42, BD Biosciences, 
San Jose, CA) as capturing antibody (50 ng/well, 610,787, 
BD Biosciences), diluted in PBS. Blocking with 1% bovine 
serum albumin was incubated on shaking for 2–4 h. Samples 
were added to wells and incubated at RT, shaking for 2 h, 
or at 4 °C O/N. The IC fractions were diluted 1000–2000 
times and the FFP fractions 20–200 times. The EV frac-
tions were not diluted prior to ELISA. Alpha-synuclein 
monomer standards (1.95–125 pM) were diluted in either 
RIPA lysis buffer or in regular ELISA incubation buffer. 
The polyclonal FL-140 (50 ng/well, sc-10,717, Santa Cruz 
Biotechnology) was used as primary detection antibody. 
For secondary detection, a goat anti-rabbit HRP antibody 
(1:5000, 31,460, Thermo Fisher Scientific) was applied fol-
lowed by the K-blue aqueous substrate (TMB). Finally, 1 M 
 H2SO4 stop solution was added and absorbance was read at 
450 nm (Infinite M1000, Tecan, Männedorf, Switzerland). 
Three independent experiments were analyzed and samples 
were run in duplicates.
Tau ELISA
The total concentrations of human tau in the samples were 
determined with the Tau Human ELISA kit (#KHB0041, 
Thermo Fisher Scientific), according to the manufacturer’s 
instructions. Samples were mixed with diluent buffer pro-
vided by the ELISA kit (FFP; 1:10,000, IC; 1:5000, and EV 
fractions; 1:2). Three independent experiments were ana-
lyzed in duplicates.
Alpha‑Synuclein Transfer Experiments
Human SH-SY5Y neuroblastoma cells were transfected with 
either V1S + SV2 (BiFC) or only V1S O/N and, after wash-
ing, incubated at 37 °C O/N in EV-depleted medium. The 
next day, the conditioned medium was collected from the 
donor cells and prepared as described above (see “Sample 
Preparation”) from four independent cultures per transfec-
tion. The samples were diluted according to the results of 
the α-syn ELISAs; the supernatant from the first ultracen-
trifugation (FFP fraction) was diluted 1:16 in EV-depleted 
medium and the pellet (EV fraction) was diluted 1:2 in 
EV-depleted medium. Non-transfected recipient cells were 
then incubated with 500 ul medium with either FFP or EV 
fractions at 37 °C O/N. At 24 h post donation, recipient 
cells were washed twice in PBS to wash away non-engulfed 
protein and fixed in 4% paraformaldehyde, blocked, followed 
by permeabilization in 5% normal goat serum in 0.1% Tri-
ton-X in PBS. The cells were incubated with primary anti-
GFP polyclonal antibodies (1:400, ab290, Abcam) at RT 
for 2 h, followed by incubation with fluorescent secondary 
antibodies (Alexa Fluor 488-linked goat anti-rabbit; 1:1000, 
A-11,008, Thermo Fisher Scientific) at RT for 1 h. Slides 
were mounted in HardSet Vectashield mounting medium 
containing DAPI (H-1500, Vector Laboratories), dried, and 
imaged with a Zen microscope (Carl Zeiss, Oberkochen, 
Germany) with a × 40 objective. A total of 22–25 images 
per well of the independent treatments were taken using the 
same settings and analyzed using a macro in ImageJ with 
preset, consistent thresholds for all images. The resulting 
area of the GFP staining was normalized against the number 
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of cells, which in turn was normalized against the mean area 
per cell from non-recipient, control cells (blank, n = 4).
Analyses and Statistics
For the α-syn ELISA, a mean value was calculated from 
the duplicate wells. The two α-syn concentration stand-
ards made in different buffers were applied to calculate 
α-syn levels in the four different fractions. For IC, FFP, and 
RIPA− EV fractions, concentrations were estimated from 
the standard curve made from dilutions in regular ELISA 
incubation buffer. The RIPA+ EV fractions were calculated 
from the standard curve made from dilutions in 1xRIPA 
lysis buffer. Total concentrations are presented as either pg/
ml or pM. The ELISA data displayed a normal distribution 
and one-way ANOVA with Dunnett’s multiple comparison 
test was carried out with the WT sample as control (Graph-
Pad Prism). Levels of significance were set to *p < 0.05, 
**p < 0.01, ***p < 0.001. Pairwise t-test comparisons 
between absolute values of RIPA+ and RIPA− were also 
made where the levels of significance were set to the same 
criteria.
For the uptake experiments, the normalized values were 
analyzed in GraphPad Prism by one-way ANOVA with Tuk-
ey’s post hoc test. Significance levels were set to *p < 0.05, 
**p < 0.01, and ***p < 0.001.
Results
Isolation of Extracellular Vesicles from Neural Cell 
Lines
In order to characterize the EV content in the SH-SY5Y 
cell-derived extracellular fractions (EV; extracellular vesi-
cles and FFP; free-floating protein), we investigated various 
markers by Western blot. The EV fractions from controls 
and α-syn transfected cells displayed clear bands for L1CAM 
and Flotillin-1 (Fig. 2a). The FFP fractions, however, did 
not seem to contain any Flotillin-1. CD63 was only mod-
estly represented in the EV fractions and not at all in the 
FFP fractions. In contrast to the other markers, Alix was not 
found in the EV fractions and only weakly in the FFP frac-
tions (Fig. 2a). The size distribution of the isolated vesicles 
was determined by NanoSight and revealed a size range of 
about 100–300 nm (Fig. 2b). Furthermore, analyses of EV 
fractions with TEM displayed enrichment of vesicles in the 
same size spectrum as detected by NanoSight (Fig. 2c). The 
enrichment of Flotillin-1 along with an apparent size distri-
bution of 100–300 nm suggests that the enriched ultracen-
trifugation pellet contained a mixture of exosomes and other 
EVs. We have therefore defined the vesicles in the enriched 
fractions with the general term extracellular vesicles. The 
FFP fractions contained debris and only a small amount of 
vesicles (Fig. 2d). Serum-depleted growth medium that had 
not been in contact with any cells was ultracentrifuged to 
analyze the background levels of EVs and FFPs. The EV 
fraction from the cell-free medium also displayed vesicles, 
albeit to a much lesser extent than that which had been col-
lected from cells (Fig. 2e). The corresponding cell-free FFP 
fraction contained particles and very few vesicles (Fig. 2f).
Tagged α‑Syn is Directed to EV‑Mediated Secretion
To assess the distribution of α-syn after expression of the 
different tagged constructs, fractions separated with ultra-
centrifugation and intracellular (IC) fractions were analyzed 
by a total α-syn sandwich ELISA. The ELISA signals in EV 
fractions varied between different transfections. In all sam-
ples, the RIPA+ signal was equal to, or only slightly higher, 
than the corresponding RIPA− signal, indicating that α-syn 
was mostly present on the outside of the membrane but to 
some extent also resided inside the EVs (Fig. 3a). Expres-
sion of V1S, SV2, as well as co-expression of V1S and SV2 
led to higher signals than WT α-syn in the FFP fraction 
(Fig. 3b). Expression of V1S as well as co-expression of 
V1S and SV2 led to higher signals than WT α-syn in the IC 
fraction (Fig. 3c).
In order to normalize for transfection differences between 
the constructs, the relative levels of α-syn in the different 
fractions were calculated as ratios of the EV fraction over 
FFP (Fig. 3d) or IC fractions (Fig. 3e). The ratio between 
EV and FFP fractions revealed a significant increase with 
the V1S construct (Fig. 3d), compared to WT-transfected 
cells. Thus, the N-terminal tag on α-syn seemed to cause a 
marked redirection in the cellular processing of α-syn. When 
EVs were normalized against IC fractions, V1S also gave 
the highest ratio of α-syn in EVs (Fig. 3e), although the 
difference between the species was smaller. In contrast to 
the tagged α-syn, the ratios of FFP versus IC fractions of 
the WT samples were significantly higher than for the other 
samples, indicating that the WT protein was secreted in the 
FFP fraction rather than via EVs (Fig. 3f).
Tau Secretion in EVs is Not Affected by GFP 
Fluorescent Tag
Based on our observation of increased levels of V1S in 
EVs versus FFPs as compared to WT α-syn, we wanted to 
explore whether a similar shift could be observed also for 
fluorescently labeled tau, another protein involved in neuro-
degeneration. Non-tagged tau and tau:GFP were expressed 
in SH-SY5Y cells. The EV-enriched and FFP fractions from 
the overexpressing cells were analyzed by ELISA.
Lysis of the EVs with RIPA buffer resulted in a signifi-
cant increase in signals for both tau constructs (Fig. 4a). 
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Signals were equal in the FFP fractions (Fig. 4b), whereas 
the tau:GFP signal was significantly higher in the IC frac-
tions (Fig. 4c). Normalization of EV fractions against FFP 
(Fig. 4d) or IC fractions (Fig. 4e) showed no significant dif-
ference of tau with or without GFP tag (Fig. 4d, e). In addi-
tion, comparisons between the amount of tau in FFP and 
IC showed similar ratios (Fig. 4f), indicating that both tau 
constructs were processed similarly in terms of secretion via 
EVs or as FFPs in the cell culture medium.
EV‑Associated N‑Tagged α‑Syn has an Increased 
Cellular Uptake
To investigate cell-to-cell transfer of EV-associated 
α-syn, donor cells were double transfected with the 
Fig. 2  The EV fractions are enriched in exosomal markers. a West-
ern blots of the lysed EVs and the corresponding FFP fractions were 
analyzed for presence of the markers L1CAM, Alix, Flotillin-1, and 
CD63. Flotillin-1 was the only marker that was highly enriched in 
all the EV fractions compared to the FFP fractions, but also CD63 
was slightly enriched in EVs, indicating that different markers may be 
differentially present in different subclasses of EVs. The membrane 
images have been cut to exclude samples outside the scope of this 
project. Unbiased contrast changes have been made to the images, but 
the unchanged, whole membrane is shown in Supplementary Fig. 1. b 
NanoSight analysis of EVs and FFP fractions showed similarly sized 
particles in samples from non-transfected (Ctrl) and tagged α-syn 
transfected cells with an average diameter of approximately 150 nm. 
The FFP fraction also contained particles of a similar size, albeit to 
a much lesser degree than the EV fraction. c TEM analysis of the 
EV-enriched fraction displayed EVs with diameters between 50 and 
500  nm. Both large high density (white arrowheads) and small less 
dense (black arrowheads) particles were highly enriched. d TEM 
analysis confirmed the NanoSight results, where small EVs (white 
arrowheads) and large, dense particles (black arrowhead) were found 
in the FFP fraction. e Ultracentrifuged growth medium containing 
EV-depleted FBS also displayed the large particles in the EV frac-
tion (white arrowheads), albeit to a much lesser degree than the EV 
fraction. f A few small EVs (black arrowheads), but no large vesicles, 
were found in the FFP after ultracentrifugation of the FBS-depleted 
growth medium
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α-syn:hemi-Venus plasmids V1S + SV2 or with V1S 
only. Conditioned medium was collected and fractions 
were isolated from four independent transfections per 
construct. Non-transfected cells received either EV or 
FFP fractions for 24 h. To discriminate between endog-
enous α-syn and externally applied α-syn and to enhance 
the signal from the internalized protein, the cells were 
stained with a polyclonal GFP antibody that binds to both 
V1S and SV2. Small punctae could be visualized in the 
recipient cells at 24 h post treatment (Fig. 5a) and the area 
difference per number of cells was analyzed after being 
normalized against background staining (data not shown). 
The staining analysis revealed a markedly increased 
uptake or prolonged retention of EV-associated V1S, as 
compared to all other fractions (Fig. 5b, p < 0.001).
Fig. 3  N-terminally tagged 
α-syn is enriched in the EV 
fraction. a Absolute levels 
of α-syn in EV (light green: 
RIPA−, dark green: RIPA+), 
b FFP fractions, and c IC frac-
tions, as measured by ELISA. 
d Percentage of α-syn in EV 
fractions compared to FFP frac-
tions. e Percentage of α-syn in 
EV compared to IC fractions. 
f Percentage of α-syn in FFP 
compared to IC fractions. The 
distribution of V1S differed 
from the other α-syn spe-
cies. Lysis of the vesicles did 
not affect the levels of α-syn, 
indicating that the protein was 
located mainly on the outside 
of the EVs. Bars represent 
mean ± SD of three independ-
ent experiments. Statistical 
significance was calculated 
by one-way ANOVA with 
Dunnett’s post hoc test, with 
levels compared to those of WT 
α-syn (*p < 0.05, **p < 0.01, 
***p < 0.001)
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A53T α‑Synuclein is Directed Towards EV Secretion
Cells were transfected with plasmids encoding the different 
familial α-syn mutants as well as WT α-syn. Measurements 
by ELISA indicated that the α-syn levels in EV fractions 
from the mutants were comparable to those for WT α-syn 
expression where most of the α-syn was present on the 
outside of the EVs (Fig. 6a). The total α-syn levels in the 
EV fractions were not significantly affected for any of the 
mutations, as compared to WT α-syn. However, the H50Q 
and G51D mutants displayed significantly increased α-syn 
signals in the lysed EVs (RIPA+), when compared to their 
corresponding native (RIPA−) EV samples, which could be 
a result of differences in binding affinity to lipid membranes 
(Stefanovic et al. 2015). Levels in the FFP fractions were 
comparable across all cells expressing either mutant or WT 
protein (Fig. 6b). The WT α-syn transfection led to signifi-
cantly higher IC levels of α-syn compared to transfection 
of mutation constructs (Fig. 6c). The ratios of EV values 
were in the range of 0.1–2% compared to FFP fractions and 
0.01–0.05% compared to IC fractions (Fig. 6d, e, respec-
tively). For A53T α-syn, there was a trend for an increased 
ratio of EV to FFP α-syn levels (Fig. 6d) and a statistically 
significant increase in the ratio of EV to IC α-syn levels 
compared to WT α-syn (Fig. 6e), both for the RIPA+ and 
RIPA− EV fractions. The ratio of FFP to IC α-syn was in 
the same range for all constructs with and without α-syn 
mutations (Fig. 6f).
Discussion
Our study lends support to the notion that exosomes and 
other EVs are involved in the spreading and/or seeding of 
α-syn, similarly to what others have found (Alvarez-Erviti 
et al. 2011; Danzer et al. 2012). The vesicles that were col-
lected from the cell medium in the present study displayed 
various sizes and were strongly displaying Flotillin-1, which 
suggests that they represent a mixture of exosomes and other 
EVs. Therefore, the vesicular secretion of α-syn could be 
attributed to either one or several types of vesicles. The vesi-
cles found in the EV and FFP fractions were of a similar size 
range (Fig. 2b–d), implying that the used protocol leads to 
an enrichment of EVs rather than a separation of large and 
small vesicles.
This study indicates that distinct presumably dysfunc-
tional forms of α-syn may alter the cellular dynamics. Most 
notably we found that V1S, one of the two α-syn:hemi-
Venus forms used in the BiFC assay for α-syn oligomeriza-
tion, was particularly prone to be directed for EV secretion, 
whereas the other form, SV2, did not seem to be secreted 
differently than regular α-syn. The underlying reason for 
the observed differences between the two α-syn:hemi-Venus 
species with respect to EV secretion is unclear, but could 
possibly be due to alterations in membrane-binding proper-
ties. It has previously been shown that fluorescent protein 
tags on the N-terminus of α-syn can alter the intracellular 
dynamics (Goncalves and Outeiro 2013) and induce vesicu-
lar secretion (Jang et al. 2010) of α-syn. In the latter study, it 
could also be shown that, depending on the nature of the tag, 
Fig. 4  No difference in tagged versus untagged tau in EV fractions. 
In order to investigate whether also tau is differentially processed via 
EVs when modified, cells were transfected with either tau or tau:GFP. 
a Absolute levels of tau in EVs, b FFP, and c IC fractions, as meas-
ured by ELISA. d Percentage of tau in EVs compared to FFP frac-
tions. e Percentage of tau in EVs compared to IC fractions. f Per-
centage of tau in FFP compared to IC fractions. In contrast to α-syn, 
the relative distribution of tau did not change when the GFP tag was 
present. Lysis of the vesicles significantly increased the levels of tau, 
indicating a large portion of the protein inside the EVs. Bars repre-
sent mean ± SD, n = 3. A t test was used to determine the significance 
between the two constructs (*p < 0.05, **p < 0.01, ***p < 0.001)
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α-syn is more or less sensitive to Proteinase K (Jang et al. 
2010). Those results and the data from the current study 
thus indicate that N-terminal protein tags on α-syn lead to 
altered membrane-binding properties and may form particu-
larly pathogenic and stable forms of aggregated α-syn that 
could increase cell-to-cell spreading. Moreover, N-terminal 
glycation of α-syn has also been shown to reduce its mem-
brane binding, leading to altered cellular α-syn processing, 
and formation of toxic oligomers (Vicente Miranda et al. 
2017). Altogether, these findings suggest that disruption of 
the membrane binding of the N-terminal portion of α-syn 
per se, rather than the presence of a fusion protein or any 
other molecule, can augment its propensity for EV secretion.
In our study, differences in expression levels were nor-
malized by analyzing ratios between the different fractions 
from one transfection. This normalization is crucial, allow-
ing comparison of relative levels in EV, FFP, and IC frac-
tions between the different α-syn species. Even though the 
different α-syn variants were expressed in the same type of 
plasmid, under the same promoter, and the amount of DNA 
used was kept constant, total α-syn levels varied substan-
tially across the different species. We realize that the dif-
ferences in total α-syn levels to some extent may affect the 
dynamics of cell distribution and processing of α-syn. On 
the other hand, these variations may be the biological effects 
of the respective α-syn variants and could be caused by dif-
ferential cellular accumulation or degradation as a result of 
variations in the oligomerization/aggregation rates. In turn, 
these factors could also have a direct impact on the extent of 
vesicular secretion of α-syn.
We could here corroborate previous findings that only a 
minor fraction (0.1−2%) of secreted α-syn are associated 
to EVs, whereas the majority of the protein can be found 
free in the extracellular space (Danzer et al. 2012; Shi et al. 
2014). Even though the EV-associated fraction of extracellu-
lar α-syn is small, such vesicles are considered to be biologi-
cally active (van Niel et al. 2006) and molecules in this envi-
ronment could be more efficiently delivered to other cells 
(Subra et al. 2010). In concurrence with Danzer et al. (2012), 
we found that certain forms of EV-associated α-syn are more 
prone to internalization or retention by a second generation 
of cells, as compared to free-floating, extracellular protein. 
This observation supports the notion that intercellular trans-
fer of pathogenic forms of α-syn could be caused by EV-
associated α-syn. Interestingly, vesicles have been shown 
to increase oligomerization of α-syn (Grey et al. 2015; Lee 
et al. 2005) and oligomers are known to negatively impact 
cellular health to a greater extent than monomers or large 
aggregates (reviewed in Ingelsson 2016). Although we can-
not say whether the observed punctae in the recipient cells 
(Fig. 5a) are derived from tagged α-syn oligomers in vesicles 
or bona fide aggregates, they could possibly be represented 
by EV-associated α-syn:hemi-Venus species that are being 
endocytosed and processed in unknown cellular trafficking 
pathways (Delenclos et al. 2017).
As we wanted to explore whether the directed exocytosis 
of V1S merely was a consequence of the cells removing 
Fig. 5  EV-associated, V1S-tagged α-syn is readily taken up by recipi-
ent cells. a Example images from cells receiving EV or FFP fractions 
from cells expressing V1S + SV2 (BiFC) or V1S only. Conditioned 
medium was added to non-transfected, SHSY5Y recipient cells for 
24  h. The cells were washed twice in PBS and, following fixation, 
immunocytochemistry against the hemi-Venus tag was performed 
to allow visualization and display both constructs independently of 
dimerization (green). b The EV-associated V1S-tagged α-syn was 
taken up or retained to a significantly greater extent than the other 
fractions. Dark purple bars represent the EV fractions and the light 
purple bars represent the FFP fractions (mean ± SD, n = 4). One-way 
ANOVA with Tukey’s post hoc test was used to determine the differ-
ences between the groups (*p < 0.05, **p < 0.01, ***p < 0.001)
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non-physiological protein forms, we also analyzed how 
another protein was processed with and without a similar 
tag. We selected tau as it, similarly to α-syn, is a protein 
involved in neurodegeneration that also forms intracellu-
lar oligomers and fibrils (Lasagna-Reeves et al. 2012) and 
that, like α-syn, has been proven to spread between cells (de 
Calignon et al. 2012; Takeda et al. 2015). Similar to α-syn, 
tau was found to be present both on the outside and the 
inside of the vesicles, although both tau and tau:GFP were 
located on the inside of the vesicles to a greater extent than 
α-syn. However, when comparing total as well as relative 
levels of tau with and without a GFP tag, we could not find 
any significant differences in the distribution to EV and FFP 
fractions between these two tau variants. These data suggest 
a selective mechanism for the differential distribution of V1S 
fusion proteins towards EVs, rather than a general phenom-
enon for non-physiological hybrid proteins.
Two of the α-syn mutants, H50Q and G51D, were found 
to end up significantly more on the inside than on the out-
side of the EVs. It has previously been shown that H50Q 
alters the interaction of α-syn with cellular membranes and 
increases its aggregation in the presence of  Cu2+ (Villar-
Pique et al. 2016), whereas G51D oligomers were found to 
have a much lower permeabilization potential compared to 
WT α-syn (Stefanovic et al. 2015). Such features may, at 
least partly, explain the differential EV localization of these 
two α-syn species that was seen in our study.
Fig. 6  A53T α-syn was enriched in the EV fraction. a Absolute levels 
of α-syn in EV (light green: RIPA–, dark green: RIPA+), b FFP and 
c IC fractions, as measured by ELISA. d Percentage of α-syn in EV 
compared to FFP fractions. e Percentage of α-syn in EV compared 
to IC fractions. f Percentage of α-syn in FFP compared to IC frac-
tions. The distribution of A53T differed from WT α-syn and the other 
mutants and was higher in both RIPA+ and RIPA− fractions when 
normalized against IC values. Bars represent mean ± SD, n = 3. Dif-
ferences between the respective RIPA− and RIPA+ fractions from 
WT α-syn were calculated by one-way ANOVA with Dunnett’s post 
hoc test (*p < 0.05, **p < 0.01, ***p < 0.001)
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A53T α-syn was the only assessed mutant that led to an 
increase in the EV-to-IC ratio. Interestingly, the total values 
for A53T in the FFP and IC fractions appeared slightly lower 
than for other mutants. As A53T α-syn has an increased 
fibrillization propensity (Giasson et al. 2002; Greenbaum 
et al. 2005), it could for this reason be differentially pro-
cessed by the cells. However, with the protocol used, it can-
not be excluded that small extracellular α-syn aggregates 
to some extent also are enriched in the EV pellet. On the 
other hand, the increased α-syn ELISA signal after addi-
tion of RIPA buffer indicates that α-syn in the EV pellet is 
associated to lipid membrane structures. It is tempting to 
speculate that the increased EV secretion of A53T α-syn 
may be driven by an increased formation of fibrillar seeds in 
the overexpressing cells. Consequently, it could be hypoth-
esized that this particular PD mutation has a higher EV con-
tribution in the propagation of pathology. Even though the 
changes were relatively small, they could be detected already 
upon 48 h of incubation and it is plausible that this mutant 
may have a more pronounced long-term impact on α-syn 
propagation in the affected brain.
In conclusion, our study suggests that α-syn species 
with presumably altered physiological properties may be 
more prone for secretion via extracellular vesicles and thus 
increase cell-to-cell spreading of pathogenic proteins. Such 
mechanisms may contribute to the propagation of pathology 
in brains from patients with α-synucleinopathies.
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